… Topotecan is currently the only drug approved in Europe in a second-line setting for the
treatment of small-cell lung cancer. … superior to topotecan as a second-line treatment in patients …

… Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase
… Organization for Research and Treatment of Cancer Early Clinical Studies Group and New …

… intravenous topotecan-based second-line chemotherapy were … The first phase III randomized
study investigating topotecan … /etoposide combination seems active in sensitive relapse; …

… was active in this population given that chemotherapy plus … Lurbinectedin compares favorably
to other drugs on the list of … phase III study of lurbinectedin/doxorubicin versus topotecan …

… Until June 2020, oral or intravenous topotecan was the only drug … two randomized phase
III trials, where topotecan showed extended … Lurbinectedin is also being actively evaluated in …

… targeted therapy and immunotherapy have also been actively tested … After relapse, topotecan
is the only second-line drug … phase II study of weekly topotecan as second-line therapy for …

… Lurbinectedin is an inhibitor of active transcription of protein-… of topotecan, as well as
other agents used in the second-line … possible pharmacokinetic drug–drug interactions and …

… Phase III trials on second-line treatments of small-cell lung … Topotecan is the only drug
currently licensed in Europe and … Newer agents do not appear to be more active than older ones. …

… Topotecan is one of the most active chemotherapeutic drugs … the only drug approved for
second-line chemotherapy for SCLC … , in a randomized phase III study comparing topotecan with …

… ones, have shown that A is active and relatively well-tolerated in … A phase III randomized trial
comparing A with topotecan in … alkylating drug Lurbinectedin (L) was evaluated in a phase II …